Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares RepurchasedShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cytek Biosciences (CTKB) Depreciation and Depletion (2020 - 2025)

Cytek Biosciences' Depreciation and Depletion history spans 6 years, with the latest figure at $1.0 million for Q4 2025.

  • For Q4 2025, Depreciation and Depletion rose 11.11% year-over-year to $1.0 million; the TTM value through Dec 2025 reached $3.9 million, up 11.43%, while the annual FY2025 figure was $3.9 million, 11.43% up from the prior year.
  • Depreciation and Depletion reached $1.0 million in Q4 2025 per CTKB's latest filing, roughly flat from $1.0 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.0 million in Q2 2025 to a low of $167000.0 in Q1 2021.
  • Average Depreciation and Depletion over 5 years is $635250.0, with a median of $700000.0 recorded in 2023.
  • Peak YoY movement for Depreciation and Depletion: surged 191.6% in 2021, then changed 0.0% in 2024.
  • A 5-year view of Depreciation and Depletion shows it stood at $347000.0 in 2021, then skyrocketed by 44.09% to $500000.0 in 2022, then surged by 60.0% to $800000.0 in 2023, then grew by 12.5% to $900000.0 in 2024, then increased by 11.11% to $1.0 million in 2025.
  • Per Business Quant, the three most recent readings for CTKB's Depreciation and Depletion are $1.0 million (Q4 2025), $1.0 million (Q3 2025), and $1.0 million (Q2 2025).